Whilst germline BRCA1 or BRCA2 PVs testing has an established role in risk management, this is increasingly relevant in the selection of therapy.1 We showed that logistic regression models built based on a large Asian population-based study of breast cancer patients, unselected for age of diagnosis and family history, outperformed the genetic risk model (BOADICEA) developed using data on European-ancestry populations and the empirical models (PENNII, KOHCal) developed using breast cancer patients with early onset or familial breast cancer. The gene discussed is BRCA1; the disease is breast cancer.